Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. [electronic resource]
Producer: 20121218Description: 322-8 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Disease Progression
- Female
- Humans
- Lymphoma, B-Cell, Marginal Zone -- drug therapy
- Male
- Middle Aged
- Rituximab
- Splenic Neoplasms -- drug therapy
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.